Regeneron Pharmaceuticals, Inc. (REGN) Stake Lowered by Rothschild Asset Management Inc.
Rothschild Asset Management Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,014 shares of the biopharmaceutical company’s stock after selling 124 shares during the period. Rothschild Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $498,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Korea Investment CORP increased its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the period. FNY Managed Accounts LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $140,000. Alpha Windward LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares during the period. Wendell David Associates Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $204,000. Finally, Welch & Forbes LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $211,000. 66.70% of the stock is owned by institutional investors.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 466.59 on Friday. The firm has a market capitalization of $49.47 billion, a PE ratio of 46.81 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The stock’s 50 day moving average is $495.54 and its 200 day moving average is $426.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current year.
WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-stake-lowered-by-rothschild-asset-management-inc/1480620.html.
A number of analysts have recently weighed in on the stock. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target for the company. in a report on Monday, April 24th. UBS AG set a $489.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $489.35.
In related news, Chairman P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the transaction, the chairman now directly owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neil Stahl sold 2,812 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $479.49, for a total transaction of $1,348,325.88. Following the completion of the transaction, the executive vice president now directly owns 28,477 shares in the company, valued at $13,654,436.73. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,922 shares of company stock worth $27,383,105. 10.40% of the stock is owned by insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.